Revolution in gene therapy for neurodegenerative disorders
AviadoBio’s mission is to transform the lives of patients living with and suffering from neurodegenerative disorders by developing and delivering transformative gene therapies for diseases including frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS).
CEO Lisa Deschamps
Advent Contact Dominic Schmidt
Private Companies
AviadoBio Announces Completion of Second Cohort in Phase 1/2 ASPIRE-FTD Clinical Trial Studying AVB-101 for FTD-GRN
Press Release. AviadoBio Announces Completion of Second Cohort in Phase 1/2 ASPIRE-FTD Clinical Trial Studying AVB-101 for FTD-GRN AVB-101 Biomarker Data Readout Expected in 2026 Clinical Milestone Shared at…
Read More
Astellas and AviadoBio Announce Exclusive Option and License Agreement for Gene Therapy AVB-101 Targeting Frontotemporal Dementia and Other Indications
Press Release. Astellas and AviadoBio Announce Exclusive Option and License Agreement for Gene Therapy AVB-101 Targeting Frontotemporal Dementia and Other Indications Astellas receives an exclusive option to license AVB-101,…
Read More
AviadoBio Announces First Patient Treated in ASPIRE-FTD Clinical Trial Evaluating AVB-101 for Frontotemporal Dementia with GRN Mutations
Press Release. AviadoBio Announces First Patient Treated in ASPIRE-FTD Clinical Trial Evaluating AVB-101 for Frontotemporal Dementia with GRN Mutations • AVB-101 is an investigational gene therapy designed to deliver…
Read More
AviadoBio Announces FDA IND Clearance and Fast Track Designation for AVB-101 for the Treatment of Frontotemporal Dementia with Progranulin (GRN) Mutations
Press Release. AviadoBio Announces FDA IND Clearance and Fast Track Designation for AVB-101 for the Treatment of Frontotemporal Dementia with Progranulin (GRN) Mutations • AVB-101 is an investigational gene…
Read More
AviadoBio Announces Initiation of Phase 1/2 Clinical Trial
Press Release. AviadoBio Announces Initiation of Phase 1/2 Clinical Trial, ASPIRE-FTD, Evaluating AVB-101 in People with Frontotemporal Dementia with GRN Mutations AVB-101 is an investigational gene therapy designed…
Read More
AviadoBio selected by Fierce Biotech as a ‘Fierce 15’ 2022 winner
Press Release. AviadoBio selected by Fierce Biotech as a ‘Fierce 15’ 2022 winner Award reinforces AviadoBio’s position as one of the most promising early-stage biotech companies in the gene…
Read More
AviadoBio to Present Pre-clinical Data on its Gene Therapy Candidate for Frontotemporal Dementia at ASGCT 2022
Press Release. Intrathalamic delivery of AVB-101 shows promising efficacy in a pre-clinical disease model Gene therapy candidate also demonstrated broad cortical expression in a large animal biodistribution study …
Read More
AviadoBio™ Raises $80 million in Series A Financing to Advance Neurodegenerative Gene Therapy Platform
Press Release. Series A led by New Enterprise Associates (NEA) and co-led by Monograph Capital follows seeding by Advent Life Sciences, Dementia Discovery Fund (DDF), F-Prime Capital, Johnson &…
Read More
